Full Text View
Tabular View
No Study Results Posted
Related Studies
Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%
This study has been completed.
First Received: June 30, 2006   Last Updated: May 30, 2007   History of Changes
Sponsored by: Innovative Medical
Information provided by: Innovative Medical
ClinicalTrials.gov Identifier: NCT00347802
  Purpose

To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.


Condition Intervention Phase
Glaucoma
 Drug: Bimatoprost 0.03%, Travoprost 0.004%
 Phase IV

Genetics Home Reference related topics: early-onset glaucoma
MedlinePlus related topics: Glaucoma
Drug Information available for: Bimatoprost Travoprost
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Single Blind, Active Control, Parallel Assignment
Official Title: Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Naive to treatment or washed off any ocular hypotensive agents
    • Untreated IOP >19 mm Hg
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete study

Exclusion Criteria:

  • · Known contraindication to bimatoprost or travoprost, or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study
    • History of intraocular surgery within the last 3 months
    • Prior discontinuation of any of the study medications for reasons related to efficacy or safety
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00347802

Locations
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Robert Noecker, MD UPMC Eye Center
  More Information

No publications provided

Study ID Numbers: 5176
Study First Received: June 30, 2006
Last Updated: May 30, 2007
ClinicalTrials.gov Identifier: NCT00347802     History of Changes
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Bimatoprost
Glaucoma
Eye Diseases
Cardiovascular Agents
 Antihypertensive Agents
Travoprost
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:
Bimatoprost
Glaucoma
Therapeutic Uses
Eye Diseases
Cardiovascular Agents
 Antihypertensive Agents
Pharmacologic Actions
Travoprost
Ocular Hypertension

ClinicalTrials.gov processed this record on May 07, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services